Thomas M. Cardillo

5.2k total citations · 1 hit paper
94 papers, 4.1k citations indexed

About

Thomas M. Cardillo is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Molecular Biology. According to data from OpenAlex, Thomas M. Cardillo has authored 94 papers receiving a total of 4.1k indexed citations (citations by other indexed papers that have themselves been cited), including 78 papers in Radiology, Nuclear Medicine and Imaging, 55 papers in Oncology and 36 papers in Molecular Biology. Recurrent topics in Thomas M. Cardillo's work include Monoclonal and Polyclonal Antibodies Research (62 papers), Radiopharmaceutical Chemistry and Applications (36 papers) and HER2/EGFR in Cancer Research (29 papers). Thomas M. Cardillo is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (62 papers), Radiopharmaceutical Chemistry and Applications (36 papers) and HER2/EGFR in Cancer Research (29 papers). Thomas M. Cardillo collaborates with scholars based in United States, Netherlands and Sweden. Thomas M. Cardillo's co-authors include David M. Goldenberg, Robert M. Sharkey, Edmund A. Rossi, Serengulam V. Govindan, Chien‐Hsing Chang, David V. Gold, Rhona Stein, Hans J. Hansen, William J. McBride and Preeti Trisal and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Thomas M. Cardillo

94 papers receiving 4.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*

2015 349 citations David M. Goldenberg, Thomas M. Cardillo et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Thomas M. Cardillo United States	38	2.4k	2.0k	1.3k	818	495	94	4.1k
Chien‐Hsing Chang United States	39	1.8k 0.7×	2.9k 1.5×	1.3k 1.0×	784 1.0×	491 1.0×	108	4.4k
Rhona Stein United States	35	1.3k 0.5×	1.8k 0.9×	866 0.7×	832 1.0×	383 0.8×	79	3.4k
Serengulam V. Govindan United States	30	2.3k 1.0×	1.8k 0.9×	905 0.7×	406 0.5×	656 1.3×	79	3.5k
Pamela A. Trail United States	29	1.5k 0.6×	1.2k 0.6×	1.7k 1.3×	474 0.6×	331 0.7×	61	3.7k
Edmund A. Rossi United States	38	1.8k 0.8×	2.9k 1.4×	1.4k 1.1×	627 0.8×	530 1.1×	85	4.3k
John Gutheil United States	17	2.3k 1.0×	1.2k 0.6×	1.1k 0.8×	404 0.5×	820 1.7×	40	4.2k
R. Katherine Alpaugh United States	37	2.6k 1.1×	996 0.5×	1.7k 1.3×	1.1k 1.4×	444 0.9×	112	4.5k
Charles G. Cerveny United States	16	2.7k 1.1×	2.4k 1.2×	1.4k 1.1×	501 0.6×	199 0.4×	26	4.1k
Teemu T. Junttila Finland	24	2.4k 1.0×	1.6k 0.8×	1.6k 1.2×	441 0.5×	740 1.5×	32	3.7k
Che‐Leung Law United States	36	1.7k 0.7×	1.5k 0.8×	1.6k 1.2×	2.3k 2.8×	229 0.5×	99	5.0k

Countries citing papers authored by Thomas M. Cardillo

Since Specialization

Citations

This map shows the geographic impact of Thomas M. Cardillo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas M. Cardillo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas M. Cardillo more than expected).

Fields of papers citing papers by Thomas M. Cardillo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas M. Cardillo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas M. Cardillo. The network helps show where Thomas M. Cardillo may publish in the future.

Co-authorship network of co-authors of Thomas M. Cardillo

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas M. Cardillo. A scholar is included among the top collaborators of Thomas M. Cardillo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas M. Cardillo. Thomas M. Cardillo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tolaney, Sara M., et al.. (2025). The Mode of Action and Clinical Outcomes of Sacituzumab Govitecan in Solid Tumors. Clinical Cancer Research. 31(8). 1390–1399. 5 indexed citations

Nessler, Ian, et al.. (2023). Improving Intracellular Delivery of an Antibody–Drug Conjugate Targeting Carcinoembryonic Antigen Increases Efficacy at Clinically Relevant Doses In Vivo. Molecular Cancer Therapeutics. 23(3). 343–353. 6 indexed citations

Chang, Chien‐Hsing, Yang Wang, Rongxiu Li, et al.. (2017). Combination Therapy with Bispecific Antibodies and PD-1 Blockade Enhances the Antitumor Potency of T Cells. Cancer Research. 77(19). 5384–5394. 67 indexed citations

Sharkey, Robert M., Serengulam V. Govindan, Thomas M. Cardillo, et al.. (2017). Selective and Concentrated Accretion of SN-38 with a CEACAM5-Targeting Antibody–Drug Conjugate (ADC), Labetuzumab Govitecan (IMMU-130). Molecular Cancer Therapeutics. 17(1). 196–203. 24 indexed citations

Cardillo, Thomas M., Serengulam V. Govindan, Diane L. Rossi, et al.. (2017). IMMU-140, a Novel SN-38 Antibody–Drug Conjugate Targeting HLA-DR, Mediates Dual Cytotoxic Effects in Hematologic Cancers and Malignant Melanoma. Molecular Cancer Therapeutics. 17(1). 150–160. 21 indexed citations

Cardillo, Thomas M., et al.. (2017). Synthetic Lethality Exploitation by an Anti–Trop-2-SN-38 Antibody–Drug Conjugate, IMMU-132, Plus PARP Inhibitors in BRCA1/2 –wild-type Triple-Negative Breast Cancer. Clinical Cancer Research. 23(13). 3405–3415. 98 indexed citations

Chang, Chien‐Hsing, et al.. (2016). Combining ABCG2 Inhibitors with IMMU-132, an Anti–Trop-2 Antibody Conjugate of SN-38, Overcomes Resistance to SN-38 in Breast and Gastric Cancers. Molecular Cancer Therapeutics. 15(8). 1910–1919. 42 indexed citations

Sharkey, Robert M., William J. McBride, Thomas M. Cardillo, et al.. (2015). Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2–SN-38 Antibody Conjugate (Sacituzumab Govitecan). Clinical Cancer Research. 21(22). 5131–5138. 130 indexed citations

Rossi, Edmund A., Diane L. Rossi, Thomas M. Cardillo, Chien‐Hsing Chang, & David M. Goldenberg. (2014). Redirected T-Cell Killing of Solid Cancers Targeted with an Anti-CD3/Trop-2–Bispecific Antibody Is Enhanced in Combination with Interferon-α. Molecular Cancer Therapeutics. 13(10). 2341–2351. 20 indexed citations

10.

Govindan, Serengulam V., Thomas M. Cardillo, Robert M. Sharkey, et al.. (2013). Milatuzumab–SN-38 Conjugates for the Treatment of CD74+ Cancers. Molecular Cancer Therapeutics. 12(6). 968–978. 107 indexed citations

11.

Sharkey, Robert M., Serengulam V. Govindan, Thomas M. Cardillo, & David M. Goldenberg. (2011). Epratuzumab–SN-38: A New Antibody–Drug Conjugate for the Therapy of Hematologic Malignancies. Molecular Cancer Therapeutics. 11(1). 224–234. 50 indexed citations

12.

Cardillo, Thomas M., Serengulam V. Govindan, Robert M. Sharkey, Preeti Trisal, & David M. Goldenberg. (2011). Humanized Anti-Trop-2 IgG-SN-38 Conjugate for Effective Treatment of Diverse Epithelial Cancers: Preclinical Studies in Human Cancer Xenograft Models and Monkeys. Clinical Cancer Research. 17(10). 3157–3169. 217 indexed citations

13.

Chang, Chien‐Hsing, Pankaj Gupta, Rosana Michel, et al.. (2010). Ranpirnase (Frog RNase) Targeted with a Humanized, Internalizing, Anti–Trop-2 Antibody Has Potent Cytotoxicity against Diverse Epithelial Cancer Cells. Molecular Cancer Therapeutics. 9(8). 2276–2286. 43 indexed citations

14.

Rossi, Edmund A., David M. Goldenberg, Thomas M. Cardillo, Rhona Stein, & Chien‐Hsing Chang. (2009). CD20-targeted tetrameric interferon-α, a novel and potent immunocytokine for the therapy of B-cell lymphomas. Blood. 114(18). 3864–3871. 57 indexed citations

15.

Govindan, Serengulam V., Thomas M. Cardillo, Sung-Ju Moon, & David Goldenberg. (2009). Abstract #3233: Targeted therapy of human colonic, lung, and pancreatic cancer xenografts, growing in nude mice, with potent antibody conjugates of SN-38. Cancer Research. 69. 3233–3233. 1 indexed citations

16.

Gold, David V., David M. Goldenberg, Habibe Karacay, et al.. (2008). A Novel Bispecific, Trivalent Antibody Construct for Targeting Pancreatic Carcinoma. Cancer Research. 68(12). 4819–4826. 53 indexed citations

17.

Rossi, Edmund A., David M. Goldenberg, Thomas M. Cardillo, et al.. (2008). Novel Designs of Multivalent Anti-CD20 Humanized Antibodies as Improved Lymphoma Therapeutics. Cancer Research. 68(20). 8384–8392. 49 indexed citations

18.

Chang, Chien‐Hsing, et al.. (2008). A modular method to prepare novel tetrameric cytokines, IFN, G-CSF, and EPO, with improved pharmacokinetics by the Dock-and-Lock (DNL) platform technology. Cancer Research. 68. 4906–4906. 2 indexed citations

19.

Gold, David V. & Thomas M. Cardillo. (2001). Monoclonal Antibody G47 Engineered to be Reactive with Colorectal Tumor Mucin. PubMed. 20(5-6). 343–350. 1 indexed citations

20.

Gold, David V., et al.. (1997). Radioimmunotherapy of experimental pancreatic cancer with131I-labeled monoclonal antibody PAM4. International Journal of Cancer. 71(4). 660–667. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact